Risk of Ovarian Cancer Relapse score: a prognostic algorithm to predict relapse following treatment for advanced ovarian cancer.
Rizzuto I. et al, (2015), Int J Gynecol Cancer, 25, 416 - 422
Sexual activity and functioning in ovarian cancer survivors: an internet-based evaluation.
Hopkins TG. et al, (2015), Climacteric, 18, 94 - 98
Harnessing Pandemonium: The Clinical Implications of Tumor Heterogeneity in Ovarian Cancer.
Blagden SP., (2015), Front Oncol, 5
OBESITY, PHYSICAL INACTIVITY AND SYMPTOMS AFTER OVARIAN CANCER TREATMENT: RESULTS FROM AN INTERNATIONAL INTERNET-BASED SURVEY
Webber K. et al, (2015), INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 25, 42 - 43
First-in-human study of CH5132799, an oral class I PI3K inhibitor, studying toxicity, pharmacokinetics, and pharmacodynamics, in patients with metastatic cancer.
Blagden S. et al, (2014), Clin Cancer Res, 20, 5908 - 5917
Application of ProTide technology to gemcitabine: a successful approach to overcome the key cancer resistance mechanisms leads to a new agent (NUC-1031) in clinical development.
Slusarczyk M. et al, (2014), J Med Chem, 57, 1531 - 1542
Developing an objective marker to optimize patient selection and predict survival benefit in early-phase cancer trials.
Stavraka C. et al, (2014), Cancer, 120, 262 - 270
Afuresertib (GSK2110183), an oral AKT kinase inhibitor, in combination with carboplatin and paclitaxel in recurrent ovarian cancer
Blagden S. et al, (2014), EUROPEAN JOURNAL OF CANCER, 50, 7 - 7
An inflammation based score can optimize the selection of patients with advanced cancer considered for early phase clinical trials.
Pinato DJ. et al, (2014), PLoS One, 9
NUC-1031: A novel ProTide that overcomes the key cancer resistance mechanisms associated with poor survival
Ghazaly EA. et al, (2014), CANCER RESEARCH, 74
The mRNA-binding protein LARP1 is a pro-survival factor that promotes tumourigenicity and chemotherapy resistance in ovarian cancer
Hopkins TG. et al, (2014), EUROPEAN JOURNAL OF CANCER, 50, S26 - S26
Weekly AUC2 carboplatin in acquired platinum-resistant ovarian cancer with or without oral phenoxodiol, a sensitizer of platinum cytotoxicity: the phase III OVATURE multicenter randomized study.
Fotopoulou C. et al, (2014), Ann Oncol, 25, 160 - 165
Intravenous versus oral dexamethasone premedication in preventing Paclitaxel infusion hypersensitivity reactions in gynecological malignancies.
O'Cathail SM. et al, (2013), Int J Gynecol Cancer, 23, 1318 - 1325
Tumour lysis syndrome in a patient with intravascular spread from a recurrent epithelial ovarian cancer
Camarata M. et al, (2013), BMJ Case Reports
Tumour lysis syndrome in a patient with intravascular spread from a recurrent epithelial ovarian cancer.
Camarata M. et al, (2013), BMJ Case Rep, 2013
Feasibility of trials in ovarian cancer by line of therapy and platinum sensitivity.
Shaboodien R. et al, (2013), Int J Gynecol Cancer, 23, 481 - 487
A study to evaluate the cause of bone demineralization in gynecological cancer survivors.
Stavraka C. et al, (2013), Oncologist, 18, 423 - 429
CONTINUOUS LOW-FLOW ASCITES-DRAINAGE AND SEQUENTIAL NON-INVASIVE TUMOR-CELL SAMPLING THROUGH THE URINARY BLADDER VIA THE ALFA-PUMP CLOSED SYSTEM IN PLATINUM-RESISTANT-OVARIAN-CANCER (PROC)
Fotopoulou C. et al, (2013), INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 23